4.4 Article

Estimated costs of prescription opioid analgesic abuse in the United States in 2001 - A societal perspective

Journal

CLINICAL JOURNAL OF PAIN
Volume 22, Issue 8, Pages 667-676

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/01.ajp.0000210915.80417.cf

Keywords

drug abuse; prescription opioid abuse; direct cost; indirect cost; economic burden

Ask authors/readers for more resources

Objectives: This study estimates the costs to society of prescription opioid analgesic (RxO) abuse in the United States. Methods: Costs associated with RxO abuse were grouped into healthcare, criminal justice, and workplace categories. Costs were estimated by either (1) a quantity method that multiplies the number of RxO abusers derived from various national surveys by the estimated per abuser cost, or (2) an apportionment method that starts with overall (ie, prescription and nonprescription) drug abuse costs for a cost component (eg, police protection) and apportions the share of costs based on the prevalence of RxO abuse relative to overall drug abuse. Medical costs in excess of those for otherwise similar nonabusers were based on an analysis of a large administrative claims database for an employed population using multivariate regression methods. Results: A lower bound estimate of the costs of RxO abuse in the United States was $8.6 billion in 2001 (or $9.5 billion in 2005 dollars). Of this amount, $2.6 billion were healthcare costs, $1.4 billion were criminal justice costs, and $4.6 billion were workplace costs. Conclusions: The costs of RxO abuse represent a substantial economic burden. Rising trends of RxO abuse suggest an escalating economic and public health burden in coming years in the United States, and potentially, elsewhere.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available